These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17885872)

  • 1. Estimating a positive false discovery rate for variable selection in pharmacogenetic studies.
    Li L; Hui S; Pennello G; Desta Z; Todd S; Nguyen A; Flockhart D
    J Biopharm Stat; 2007; 17(5):883-902. PubMed ID: 17885872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis.
    Liu P; Hwang JT
    Bioinformatics; 2007 Mar; 23(6):739-46. PubMed ID: 17237060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for the false discovery rate.
    Pounds S; Cheng C
    Bioinformatics; 2005 Dec; 21(23):4263-71. PubMed ID: 16204346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of using multiple stepwise algorithms for variable selection.
    Wiegand RE
    Stat Med; 2010 Jul; 29(15):1647-59. PubMed ID: 20552568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bootstrap model selection had similar performance for selecting authentic and noise variables compared to backward variable elimination: a simulation study.
    Austin PC
    J Clin Epidemiol; 2008 Oct; 61(10):1009-17.e1. PubMed ID: 18539429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric bayesian estimation of positive false discovery rates.
    Tang Y; Ghosal S; Roy A
    Biometrics; 2007 Dec; 63(4):1126-34. PubMed ID: 17501943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
    Flockhart D
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):493-4. PubMed ID: 18654115
    [No Abstract]   [Full Text] [Related]  

  • 8. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
    Nixon RM; Duffy SW
    J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen.
    Nurs Times; 2006 Feb 21-27; 102(8):33. PubMed ID: 16519033
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data.
    Shedden K; Chen W; Kuick R; Ghosh D; Macdonald J; Cho KR; Giordano TJ; Gruber SB; Fearon ER; Taylor JM; Hanash S
    BMC Bioinformatics; 2005 Feb; 6():26. PubMed ID: 15705192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple test procedures using an upper bound of the number of true hypotheses and their use for evaluating high-dimensional EEG data.
    Hemmelmann C; Ziegler A; Guiard V; Weiss S; Walther M; Vollandt R
    J Neurosci Methods; 2008 May; 170(1):158-64. PubMed ID: 18279970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer.
    Ferretti G; Mandalà M; Bria E; Carlini P; Papaldo P; Fabi A; Felici A; Cognetti F
    Breast Cancer Res Treat; 2005 Apr; 90(3):319. PubMed ID: 15830147
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating the false discovery rate using nonparametric deconvolution.
    van de Wiel MA; Kim KI
    Biometrics; 2007 Sep; 63(3):806-15. PubMed ID: 17825012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetic testing: soon before every prescription?].
    Buclin T; Colombo S; Biollaz J
    Rev Med Suisse; 2008 Jul; 4(165):1666-70. PubMed ID: 18767293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the sample size requirement in genetic association tests when the proportion of false positives is controlled.
    Zou G; Zuo Y
    Genetics; 2006 Jan; 172(1):687-91. PubMed ID: 16204206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure antiestrogens as a new therapy for breast cancer.
    England GM; Jordan VC
    Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.